CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine

被引：0
|
作者：
Xinna Zhou
Guoliang Qiao
Xiaoli Wang
Qingkun Song
Michael A. Morse
Amy Hobeika
William R. Gwin
Jun Ren
H. Kim Lyerly
机构：
[1] Capital Medical University Cancer Center,Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines
[2] Beijing Shijitan Hospital,Department of Medical Oncology
[3] Capital Medical University,Department of Medicine
[4] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),Department of Surgery
[5] Beijing Cancer Hospital and Institute,Department of Medicine
[6] Peking University School of Oncology,undefined
[7] Duke University Medical Center,undefined
[8] Duke University Medical Center,undefined
[9] University of Washington,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
CYP1A1; Single nucleotide polymorphism; Breast cancer; Liver metastasis; Docetaxel; Thiotepa; Capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：365 / 372
页数：7
相关论文
共 50 条
  • [21] The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa
    Qingkun Song
    Xinna Zhou
    Jing Yu
    Ningning Dong
    Xiaoli Wang
    Huabing Yang
    Jun Ren
    H Kim Lyerly
    Scientific Reports, 5
  • [22] The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa
    Song, Qingkun
    Zhou, Xinna
    Yu, Jing
    Dong, Ningning
    Wang, Xiaoli
    Yang, Huabing
    Ren, Jun
    Lyerly, H. Kim
    SCIENTIFIC REPORTS, 2015, 5
  • [23] BRCA1 AND EGFR AS PROGNOSTIC BIOMARKERS IN TRIPLE NEGATIVE METASTATIC BREAST CANCER PATIENTS TREATED WITH CISPLATIN PLUS DOCETAXEL
    Ezz, L. R.
    El Mahdy, M. M.
    el Karim, K. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 40 - 40
  • [24] Combination chemotherapy: docetaxel plus cisplatin for patients with metastatic breast cancer resistant to previous anthracycline treatment
    Krasteva-Ruseva, R
    Zahariev, Z
    ANNALS OF ONCOLOGY, 2005, 16 : 279 - 279
  • [25] Responses to docetaxel plus virorelbine in metastatic breast cancer patients failing high-dose chemotherapy
    Andres, R
    Mayordomo, JI
    Isla, D
    Marti, JL
    Escudero, P
    Filipovich, E
    Saenz, A
    Alvarez, I
    Polo, E
    Tres, A
    BRITISH JOURNAL OF CANCER, 2002, 86 (06) : 1017 - 1018
  • [26] Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy
    R Andres
    J I Mayordomo
    D Isla
    J L Marti
    P Escudero
    E Filipovich
    A Saenz
    I Alvarez
    E Polo
    A Tres
    British Journal of Cancer, 2002, 86 : 1017 - 1018
  • [27] Activity and safety of biweekly docetaxel plus capecitabine as first-line treatment for patients with metastatic breast cancer.
    Llorca, C
    Mayordomo, J
    Adrover, E
    Alvarez, I
    Madroñal, C
    Burillo, M
    Sanz, J
    Lorenzo, A
    Palombo, H
    Janariz, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 73S - 73S
  • [28] Feasibility of adjuvant chemotherapy with doxorubicin plus docetaxel followed by sequential capecitabine in patients with node positive breast cancer.
    Lara, R
    Mayordomo, JI
    Modolell, A
    Burillo, M
    Sanz, J
    Murillo, L
    Janariz, J
    Perez, V
    Andres, R
    Tres, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 72S - 72S
  • [29] A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report
    Mavroudis, D
    Boukovinas, I
    Ardavanis, A
    Syrigos, K
    Kouroussis, CH
    Kakolyris, S
    Malamos, N
    Athanasiadis, A
    Varthalitis, I
    Potamianou, A
    Georgoulias, V
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S280
  • [30] ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
    Kim, Hee-Jun
    Im, Seock-Ah
    Keam, Bhumsuk
    Ham, Hye Seon
    Lee, Kyung Hun
    Kim, Tae Yong
    Kim, Yu Jung
    Oh, Do-Youn
    Kim, Jee Hyun
    Han, Wonshik
    Jang, In-Jin
    Kim, Tae-You
    Park, In Ae
    Noh, Dong Young
    CANCER SCIENCE, 2015, 106 (01): : 86 - 93
12345